|Courtesy of Vessix Vascular|
What To Know: Amid all these publicly held device giants, there's also Laguna Hills, CA's Vessix Vascular and its V2 renal denervation system. While Vessix may lack the staffing and promotional budgets of Medtronic or St. Jude Medical, it does have a CE marked balloon catheter that can ablate 8 spots on the renal artery in one to two minutes, making it 7 times faster than Symplicity, the company says. Vessix is backed by Orbimed and Edmond de Rothschild, and the company is using a $23 million funding round from last year to conduct a post-market surveillance study of 120 patients in Europe and Australia, amassing clinical data it'll use to pitch V2 to more physicians and vascular centers.
What's Next: Vessix is plotting a full-scale commercial launch in Europe for the beginning of 2013, looking to snag a share of the already competitive market for hypertension-treating devices overseas. From there, the company will continue collecting safety and efficacy data before engaging the FDA in 2015, Vessix says.
Release: Vessix receives CE mark for V2 renal denervation system
Release: Vessix treats first patient in V2 clinical study
Release: Vessix Vascular completes $23M financing